DFDavid P. Foley

David P. Foley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David P. Foley has a total of 167 co-authors. Here are the top co-authors by number of shared publications:

  • Dominic Amara

    Department of Surgery, University of California Los Angeles, Los Angeles, CA

    3 shared publications
  • Drew Roenneburg

    Department of Surgery,University of Wisconsin School of Medicine and Public Health,Madison,WI

    3 shared publications
  • Joshua D. Mezrich

    Division of Transplantation,University of Wisconsin School of Medicine and Public Health,Madison,WI

    3 shared publications
  • Luis A. Fernandez

    Department of Surgery, University of Wisconsin, Madison, WI, USA

    3 shared publications
  • Lung-Yi Lee

    Department of Surgery, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii

    3 shared publications
  • Sabine Werner

    Department of Biology, Institute of Molecular Health Sciences,Swiss Federal Institute of Technology,Zurich,Switzerland

    3 shared publications

Latest Publications

  • Open Access

    IL35 Production After Living-donor Renal Transplantation: Relevance to Local, Exosome-mediated, Clinical Tolerance

    by William J. Burlingham, John H. Fechner, Ewa Jankowska-Gan, Sudipta Tripathi, Brittany L. Schreiber, Anil Chandraker, Dixon B. Kaufman, David P. Foley

    Background.: We previously reported that 100% of HLA-identical siblings and 50% of HLA-haploidentical donor-recipient pairs exhibited bidirectional immunoregulation (BDIR) before living-related renal transplantation. BDIR predicted successful transplant outcomes. However, at the time, we were unaware of the role of the cytokine interleukin-35 (IL35) in immunoregulation, and we now appreciate exosomes as a means of confining immunoregulation to the transplanted tissue. Here we show that HLA-identical sibling transplants use IL35 in posttransplant BDIR. Methods.: We analyzed the posttransplant IL35 response using the trans-vivo delayed type hypersensitivity assay in HLA-identical sibling transplants, using anti-IL35 antibodies to block immune-regulatory function as measured by either (1) inhibition of the tetanus toxoid/diphtheria toxoid recall response or (2) uncovering of direct response, in both the donor anti-recipient and the recipient anti-donor (minor H) antigen directions. Results.: We found that minor antigen-specific human regulatory T cells, known to be present in peripheral blood mononuclear cell of HLA-identical siblings pretransplant, also caused BDIR via production of IL35 posttransplant. Conclusions.: We conclude that human IL35 is a component of BDIR in HLA-identical sibling transplantation. Since IL35 is one of a subclass of exosome-delivered cytokines, this means that human IL35 could sustain local BDIR within the transplant itself. It follows that local BDIR would persist indefinitely if donor leukocytes were allowed to stably engraft. This may account for the success of combined total lymphoid irradiation/bone marrow transplantation/renal transplantation induction of stable tolerance in HLA-identical sibling transplant recipients.


  • The History of DCD Liver Transplant

    by Ashley N. Krepline, David P. Foley

  • Open Access

    Comparison of Laparoscopic and Hand-assisted Live Donor Nephrectomy: An Analysis of NSQIP Transplant

    by Dominic Amara, Arielle Grieco, Karina Covarrubias, Yaoming Liu, Peter G. Stock, David Foley, Stuart Greenstein, Ryutaro Hirose, Justin R. Parekh

    Background.: Pure laparoscopic and hand-assisted approaches are the predominant techniques for living donor nephrectomy, yet high-quality multicenter comparisons remain limited. Methods.: Using prospectively collected data from the American College of Surgeons National Surgical Quality Improvement Program Transplant pilot (from March 2017 to July 2020), we compared outcomes between pure laparoscopic and hand-assisted donor nephrectomy. Outcomes included operative duration, postoperative length of stay (LOS), and 30-d unplanned readmission. Mixed-effects linear, Poisson, and logistic regression models with hospital-level random intercepts quantified center variation and the independent association of surgical approach with outcomes. Results.: Among 1542 donors, 890 (57.7%) underwent pure laparoscopic and 652 (42.3%) hand-assisted nephrectomies. Donors were predominantly female (63%), mean age 43.4 y, and 61.8% were overweight or obese. Pure laparoscopic procedures had longer operative times (180 versus 150 min; P < 0.001). Median LOS was similar (2 d for both), although pure laparoscopy had more extended-stay cases ( P < 0.001). Readmission was rare and comparable (2.4% versus 2.9%; pure laparoscopic versus hand-assisted; P = 0.50). Center-level variation was substantial for operative duration (intraclass correlation coefficient = 0.51), and notable for LOS (median rate ratio [RR] = 1.25) and readmission (median odds ratio = 1.60). In unadjusted and adjusted models, pure laparoscopy was not associated with differences in operative duration relative to hand-assisted (β = 5.05 min; 95% confidence interval [CI], –4.56 to 14.66 and adjusted β = 5.59; 95% CI, –3.71 to 14.88), LOS (RR = 0.99; 95% CI, 0.87-1.13 and adjusted RR = 0.98; 95% CI, 0.86-1.12), or readmission (odds ratio = 0.63; 95% CI, 0.28-1.44). Conclusions.: In this national, multicenter analysis using prospectively collected data, pure laparoscopic and hand-assisted donor nephrectomy demonstrated similar perioperative outcomes and very low complication rates. Surgical approach did not independently influence operative duration or LOS. Readmission was rare. Substantial center-level variation suggests institutional practice patterns may play a larger role than technique selection.

  • Open Access

    Left Ventricular Ejection Fraction and Previous Cardiac Revascularization: Impact on Patient Survival, Graft Survival, and Complications in Kidney Transplant Recipients

    by Dominic Md Amara, Miguel Nunez, Justin Parekh, Stuart Greenstein, David Foley, Peter Stock, Ryutaro Hirose

    Background.: Kidney transplant physicians believe that the cardiac status of kidney transplant recipients influences posttransplant outcomes. However, the Scientific Registry of Transplant Recipients (SRTR) does not include cardiac variables in its risk-adjustment model, raising the question of whether it fairly risk adjusts recipients. Methods.: This study conducted a retrospective analysis of the prospectively collected National Surgical Quality Improvement Program Transplant database to assess the impacts of pretransplant cardiac revascularization and left ventricular ejection fraction (LVEF) P = 0.001), delayed graft function (39.2% versus 28.3%, P < 0.001), myocardial infarction (4.4% versus 0.8%, P < 0.001), longer length of stay (6.57 versus 5.54 d, P = 0.001), and more readmissions (32.9% versus 23.1%, P < 0.001). In univariable analysis, previous revascularization was associated with death (hazard ratio [HR], 2.4; 95% confidence interval [CI], 1.11-5.1; P = 0.03) but not graft loss (HR, 1.3; 95% CI, 0.54-3.1; P = 0.55). LVEF P = 0.011). After adjusting for SRTR variables (age, diabetes, peripheral vascular disease), previous revascularization was not independently associated with death (HR, 1.33; 95% CI, 0.57-3.1; P = 0.50). Conclusions.: Previous cardiac revascularization is associated with patient survival and complications, more than LVEF <55%. However, we show that existing variables of the SRTR risk model largely capture the impact of previous cardiac revascularization on patient survival.


  • Open Access

    Twelve Thousand Kidney Transplants Over More Than 55 Y: A Single-center Experience

    by Sandesh Parajuli, Jacqueline Garonzik-Wang, Brad C. Astor, Fahad Aziz, Neetika Garg, Bridget Mha/Inf Welch, Jon Odorico, Joshua Mezrich, Dixon Kaufman, David P. Foley, et al.

    Background. Kidney transplant outcomes have dramatically improved since the first successful transplant in 1954. In its early years, kidney transplantation was viewed more skeptically. Today it is considered the treatment of choice among patients with end-stage kidney disease. Methods. Our program performed its first kidney transplant in 1966 and recently performed our 12 000th kidney transplant. Here, we review and describe our experience with these 12 000 transplants. Transplant recipients were analyzed by decade of date of transplant: 1966–1975, 1976–1985, 1986–1995, 1996–2005, 2006–2015, and 2016–2022. Death-censored graft failure and mortality were outcomes of interest. Results. Of 12 000 kidneys, 247 were transplanted from 1966 to 1975, 1147 from 1976 to 1985, 2194 from 1986 to 1995, 3147 from 1996 to 2005, 3046 from 2006 to 2015, and 2219 from 2016 to 2022 compared with 1966–1975, there were statistically significant and progressively lower risks of death-censored graft failure at 1 y, 5 y, and at last follow-up in all subsequent eras. Although mortality at 1 y was lower in all subsequent eras after 1986–1995, there was no difference in mortality at 5 y or the last follow-up between eras. Conclusions. In this large cohort of 12 000 kidneys from a single center, we observed significant improvement in outcomes over time. Kidney transplantation remains a robust and ever-growing and improving field.


  • Strategies to Improve the Utilization and Function of DCD Livers

    by Steven C. Kim, David P. Foley

    Despite the increased usage of livers from donation after circulatory death (DCD) donors in the last decade, many patients remaining on the waitlist who need a liver transplant. Recent efforts have focused on maximizing the utilization and outcomes of these allografts using advances in machine perfusion technology and other perioperative strategies such as normothermic regional perfusion (NRP). In addition to the standard donor and recipient matching that is required with DCD donation, new data regarding the impact of graft steatosis, extensive European experience with NRP, and the increasing use of normothermic and hypothermic machine perfusion have shown immense potential in increasing DCD organ overall utilization and improved outcomes. These techniques, along with viability testing of extended criteria donors, have generated early promising data to consider the use of higher-risk donor organs and more widespread adoption of these techniques in the United States. This review explores the most recent international literature regarding strategies to optimize the utilization and outcomes of DCD liver allografts, including donor–recipient matching, perioperative strategies including NRP versus rapid controlled DCD recovery, viability assessment of discarded livers, and postoperative strategies including machine perfusion versus pharmacologic interventions.


  • Open Access

    Extracellular Vesicle–associated GARP/TGFβ:LAP Mediates “Infectious” Allo-tolerance

    by William J. Burlingham, Ewa Jankowska-Gan, John H. Fechner, Christopher J. Little, Jianxin Wang, Seungpyo Hong, Miraf Bs Molla, Jeremy A. Sullivan, David P. Foley

    Background.: Here we test the hypothesis that, like CD81-associated “latent” IL35, the transforming growth factor (TGF)β:latency-associated peptide (LAP)/glycoprotein A repetitions predominant (GARP) complex was also tethered to small extracellular vesicles (sEVs), aka exosomes, produced by lymphocytes from allo-tolerized mice. Once these sEVs are taken up by conventional T cells, we also test whether TGFβ could be activated suppressing the local immune response. Methods.: C57BL/6 mice were tolerized by i.p. injection of CBA/J splenocytes followed by anti-CD40L/CD154 antibody treatment on days 0, 2, and 4. On day 35, spleen and lymph nodes were extracted and isolated lymphocytes were restimulated with sonicates of CBA splenocytes overnight. sEVs were extracted from culture supernatants by ultracentrifugation (100 000g) and assayed for (a) the presence of TGFβ:LAP associated with tetraspanins CD81,CD63, and CD9 by enzyme-linked immunosorbent assay; (b) GARP, critical to membrane association of TGFβ:LAP and to activation from its latent form, as well as various TGFβ receptors; and (c) TGFβ-dependent function in 1° and 2° immunosuppression of tetanus toxoid-immunized B6 splenocytes using trans-vivo delayed–type hypersensitivity assay. Results.: After tolerization, CBA-restimulated lymphocytes secreted GARP/TGFβ:LAP-coated extracellular vesicles. Like IL35 subunits, but unlike IL10, which was absent from ultracentrifuge pellets, GARP/TGFβ:LAP was mainly associated with CD81+ exosomes. sEV-bound GARP/TGFβ:LAP became active in both 1° and 2° immunosuppression, the latter requiring sEV uptake by “bystander” T cells and reexpression on the cell surface. Conclusions.: Like other immune-suppressive components of the Treg exosome, which are produced in a latent form, exosomal GARP/TGFβ:LAP produced by allo-specific regulatory T cells undergoes either immediate activation (1° suppression) or internalization by naive T cells, followed by surface reexpression and subsequent activation (2°), to become suppressive. Our results imply a membrane-associated form of TGFβ:LAP that, like exosomal IL35, can target “bystander” lymphocytes. This new finding implicates exosomal TGFβ:LAP along with Treg-derived GARP as part of the infectious tolerance network.


  • Open Access

    Psychosocial assessment in liver transplantation (LT): an analysis of short-term outcomes

    by Lindsay A. Matthews, Jessica A. Musto, Nimrod Deiss-Yehiely, Kimberly E. Daniel, Christina Lightbourn, Maureen Garvey, Fay Osman, David P. Foley, John R. Rice, Michael R. Lucey

    Background: Our research showed that patients with alcohol-associated liver disease (ALD) had more severe liver disease than those without a diagnosis of ALD yet were less likely to be selected for transplant listing due to their increased psychosocial vulnerability. This study aims to answer whether this vulnerability translates to worse short-term outcomes after transplant listing. Methods: A total of 187 patients were approved for liver transplant listing and are included in the present retrospective study. We collected dates of transplantation, retransplantation, death, and pathologic data for evidence of rejection, and reviewed alcohol biomarkers and documentation for evidence of alcohol use. Results: The ALD cohort had higher Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) scores (39.4 vs. 22.5, p p p =0.71) subjects without ALD subsequently received a liver transplant. Overall mortality was similar between the 2 groups (20.7% ALD vs. 21.0% non-ALD, p =0.97). Neither the SIPAT score (HR: 0.98, 95% CI: 0.96–1.00, p =0.11) nor MELD-Na score (HR 0.99, 95% CI 0.95-1.02, p =0.40) were associated with mortality. Patients with ALD were more likely to have alcohol biomarkers tested both before (84.1% vs. 24.8% non-ALD, p p p =0.04), although a return to alcohol use was not associated with mortality (HR: 1.60, 95% CI: 0.63–4.10, p =0.33). Conclusion: Patients with ALD had higher psychosocial risk compared with patients without a diagnosis of ALD who were placed on the waitlist, but had similar short-term outcomes including mortality, transplantation, and rejection. Although a high SIPAT score was predictive of alcohol use, in the short-term, alcohol use after transplant listing was not associated with mortality.


  • Open Access

    331.6: Impact of Left Ventricular Ejection Fraction and Previous Cardiac Revascularization on Patient and Graft Survival in Kidney Transplant Receipts

    by Dominic Amara, Miguel Nunez, Justin Parekh, David Foley, Stuart Greenstein, Ryutaro Hirose

  • Open Access

    Liver Transplantation as a New Standard of Care in Patients With Perihilar Cholangiocarcinoma? Results From an International Benchmark Study

    by Eva Breuer, Matteo Mueller, Majella B. Md Doyle, Liu Yang, Sarwa Darwish Murad, Imran J. Anwar, Shaheed Merani, Ashley Limkemann, Heithem Jeddou, Steven C. Kim, et al.

    Objective: To define benchmark values for liver transplantation (LT) in patients with perihilar cholangiocarcinoma (PHC) enabling unbiased comparisons. Background: Transplantation for PHC is used with reluctance in many centers and even contraindicated in several countries. Although benchmark values for LT are available, there is a lack of specific data on LT performed for PHC. Methods: PHC patients considered for LT after Mayo-like protocol were analyzed in 17 reference centers in 2 continents over the recent 5-year period (2014–2018). The minimum follow-up was 1 year. Benchmark patients were defined as operated at high-volume centers (≥50 overall LT/year) after neoadjuvant chemoradiotherapy, with a tumor diameter P<0.001). Conclusion: This multicenter benchmark study demonstrates that LT offers excellent outcomes with superior oncological results in early stage PHC patients, even in candidates for surgery. This provocative observation should lead to a change in available therapeutic algorithms for PHC.